Physician profile
Aaron E Packham
NPI 1912356718
$881.45
in general payments reported to CMS, 2019-2025
23 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.40 · 2022: $25.09 · 2023: $84.97 · 2024: $267 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $173.58 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $103.89 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $63.62 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $51.52 | 2024-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $50.94 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $49.03 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $38.11 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $36.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.77 | 2020 | |
| Abbvie INC. | $30.85 | 2025 | |
| Abbott Laboratories | $24.89 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $24.76 | 2024 | Yupelri |
| Glaxosmithkline, LLC. | $24.74 | 2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $23.48 | 2025 | M-M-R II, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.87 | 2024 | Xifaxan, Trulance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $19.37 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.31 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $17.53 | 2024 | Spravato |
| Vanda Pharmaceuticals INC. | $17.13 | 2025 | Ponvory |
| Xeris Pharmaceuticals, INC. | $16.88 | 2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $16.58 | 2025 | Inspire |
| Boston Scientific Corporation | $14.35 | 2024 | |
| Lilly USA, LLC | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Packham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.